Abstract
Hereditary spinocerebellar ataxia (SCA) is a devastating, incurable disease. Stem-cell-based therapies represent new promise for clinical research in neurology. The objectives of this study were to assess the feasibility, efficacy, and potential toxicity of human umbilical cord mesenchymal stem cells (UCMSCs) therapy in patients with SCA. Sixteen genomically diagnosed SCA patients were enrolled and received intravenous and intrathecal infusion of UCMSCs. Clinical, laboratory, and radiographic evaluations were conducted to assess the safety of UCMSC therapy. Efficacy was evaluated by the Berg Balance Scale (BBS) and International Cooperative Ataxia Rating Scale (ICARS) scores. Among the 16 cases, there were no serious transplant-related adverse events happened in 12 months follow-up. The majority of patients showed improved BBS and ICARS scores continuing for at least 6 months which indicated UCMSC therapy could alleviate SCA symptoms. This study suggested that UCMSC transplantation was safe and might delay the progression of SCA. This may represent a new therapeutic strategy for SCA and other genetic neurological diseases.
Keywords: Berg Balance Scale, Efficacy, International Cooperative Ataxia Rating Scale, Safety, Spinocerebellar Ataxia, Umbilical Cord Mesenchymal Stem Cell
Current Neurovascular Research
Title:Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellar Ataxia
Volume: 10 Issue: 1
Author(s): Jia-Li Jin, Zhuo Liu, Zhen-Juan Lu, De-Ning Guan, Chong Wang, Zhi-Bin Chen, Jun Zhang, Wei-Yun Zhang, Jia-Yong Wu and Yun Xu
Affiliation:
Keywords: Berg Balance Scale, Efficacy, International Cooperative Ataxia Rating Scale, Safety, Spinocerebellar Ataxia, Umbilical Cord Mesenchymal Stem Cell
Abstract: Hereditary spinocerebellar ataxia (SCA) is a devastating, incurable disease. Stem-cell-based therapies represent new promise for clinical research in neurology. The objectives of this study were to assess the feasibility, efficacy, and potential toxicity of human umbilical cord mesenchymal stem cells (UCMSCs) therapy in patients with SCA. Sixteen genomically diagnosed SCA patients were enrolled and received intravenous and intrathecal infusion of UCMSCs. Clinical, laboratory, and radiographic evaluations were conducted to assess the safety of UCMSC therapy. Efficacy was evaluated by the Berg Balance Scale (BBS) and International Cooperative Ataxia Rating Scale (ICARS) scores. Among the 16 cases, there were no serious transplant-related adverse events happened in 12 months follow-up. The majority of patients showed improved BBS and ICARS scores continuing for at least 6 months which indicated UCMSC therapy could alleviate SCA symptoms. This study suggested that UCMSC transplantation was safe and might delay the progression of SCA. This may represent a new therapeutic strategy for SCA and other genetic neurological diseases.
Export Options
About this article
Cite this article as:
Jin Jia-Li, Liu Zhuo, Lu Zhen-Juan, Guan De-Ning, Wang Chong, Chen Zhi-Bin, Zhang Jun, Zhang Wei-Yun, Wu Jia-Yong and Xu Yun, Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellar Ataxia, Current Neurovascular Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567202611310010003
DOI https://dx.doi.org/10.2174/1567202611310010003 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Current Alzheimer Research Editorial (Is there a Need for Safety Monitoring Guidelines for Antidepressant Treatment?)
Current Drug Safety Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience
Current Pharmaceutical Design Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer
Current Drug Metabolism Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design FDG-PET for Prediction of AD Dementia in Mild Cognitive Impairment. A Review of the State of the Art with Particular Emphasis on the Comparison with Other Neuroimaging Modalities (MRI and Perfusion SPECT)
Current Alzheimer Research Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions
Endocrine, Metabolic & Immune Disorders - Drug Targets Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Use of Biochemical and Microscopic Techniques to Determine Enhanced Skin Permeation of Nanovesicles: A Mechanistic Study
Pharmaceutical Nanotechnology The Anti-Migraine Effects of M2000 (β-D-Mannuronic Acid) on a Patient with Rheumatoid Arthritis: Case Report
Current Clinical Pharmacology Carvedilol Promotes Retinal Ganglion Cell Survival Following Optic Nerve Injury via ASK1-p38 MAPK Pathway
CNS & Neurological Disorders - Drug Targets Clinical Implication of Meissner’s Corpuscles
CNS & Neurological Disorders - Drug Targets Home Oxygen Therapy for the 21st Century
Current Respiratory Medicine Reviews Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Do Substance P and the NK1 Receptor have a Role in Depression and Anxiety?
Current Pharmaceutical Design Experimental Temperature Compensation on Drop-On-Demand Inkjet Printing
Micro and Nanosystems Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Current Bioactive Compounds